Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Rituximab 29Surveys and Questionnaires 25Blood Specimen Collection 17Gene Expression Profiling 15Flow Cytometry 14Polymerase Chain Reaction 13Amplified Fragment Length Polymorphism Analysis 13Microarray Analysis 11Observation 10Interviews as Topic 10Psychiatric Rehabilitation 9Lenalidomide 9Immunohistochemistry 9Cytogenetic Analysis 9obinutuzumab 8Watchful Waiting 8Therapeutics 8ibrutinib 7Drug Therapy 7Cyclophosphamide 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6fludarabine 5In Situ Hybridization, Fluorescence 5Immunologic Techniques 5Data Collection 5Brentuximab Vedotin 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × fluoroazomycin arabinoside × Lymphoid × Clear all
NCT04409314 2023-08-21

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

University of California, San Francisco

Completed
23 enrolled
LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡